【Takeda Pharmaceutical】Notice of Cancellation and New Registration of Share Issuance and Regarding LTIP｜June 2026

Overview of Capital Policy

Takeda Pharmaceutical decided to cancel the registration of the share issuance submitted in June 2025 and to register a new issuance in relation to the implementation of the LTIP (Long-Term Incentive Plan). The purpose of this new registration is to enable flexible share issuances and disposal of treasury stock. The maximum planned amount is estimated at 240 billion yen. It is not aimed at fundraising, but limited to stock grants based on the LTIP, with a projected dilutive impact of about 1.1%. The issuance period is from June 9, 2026, to June 8, 2027.

Impact on Shareholders and Future Outlook

This capital policy aims to continue the LTIP and strengthen employee incentives. Since it does not involve fundraising, the direct impact on shareholders' ownership ratios is limited. The upper limit of the planned issuance amount is 240 billion yen, with an estimated dilutive rate of about 1.1%. Going forward, Takeda Pharmaceutical will continue to promote flexible capital policy with the goal of enhancing long-term corporate value through employee incentive schemes.